Loxoprofen Sodium, a Non-Selective NSAID, Reduces Atherosclerosis in Mice by Reducing Inflammation
Open Access
- 1 January 2010
- journal article
- Published by The Society for Free Radical Research Japan in Journal of Clinical Biochemistry and Nutrition
- Vol. 47 (2) , 138-147
Abstract
Recently, it is suggested that the use of nonsteroidal anti-inflammatory drugs (NSAID) may contribute to the occurrence of cardiovascular events, while the formation of atherosclerotic lesions is related to inflammation. Loxoprofen sodium, a non-selective NSAID, becomes active after metabolism in the body and inhibits the activation of cyclooxygenase. We fed apoE−/− mice a western diet from 8 to 16 weeks of age and administered loxoprofen sodium. We measured atherosclerotic lesions at the aortic root. We examined serum levels of cholesterol and triglycerides with HPLC, platelet aggregation, and urinary prostaglandin metabolites with enzyme immune assay. Atherosclerotic lesion formation was reduced to 63.5% and 41.5% as compared to the control in male and female apoE−/− mice treated with loxoprofen sodium respectively. Urinary metabolites of prostaglandin E2, F1α, and thromboxane B2, and platelet aggregation were decreased in mice treated with loxoprofen sodium. Serum levels of cholesterol and triglycerides were not changed. We conclude that loxoprofen sodium reduced the formation of early to intermediate atherosclerotic lesions at the proximal aorta in mice mediated by an anti-inflammatory effect.Keywords
This publication has 22 references indexed in Scilit:
- A Questionnaire-Based Survey on the Prescription of Non-Steroidal Anti-Inflammatory Drugs by Physicians in East Asian Countries in 2007Digestion, 2009
- Premature atherosclerotic cardiovascular disease in systemic lupus erythematosusArthritis & Rheumatism, 2007
- Risk of Cardiovascular Events in Patients Receiving Celecoxib: A Meta-Analysis of Randomized Clinical TrialsThe American Journal of Cardiology, 2007
- Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosusProceedings of the National Academy of Sciences, 2006
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryNew England Journal of Medicine, 2005
- Identification of Unique Lipoprotein Subclasses for Visceral Obesity by Component Analysis of Cholesterol Profile in High-Performance Liquid ChromatographyArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Survival in rheumatoid arthritis: A population‐based analysis of trends over 40 yearsArthritis & Rheumatism, 2003
- Characterization of platelet aggregation in whole blood of laboratory animals by a screen filtration pressure methodPlatelets, 2003
- Accelerated atherosclerosis: An extraarticular feature of rheumatoid arthritis?Arthritis & Rheumatism, 2002
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000